Watch BIOA. Know when insiders buy.
One email the day a filing lands. Free.
BIOA
BioAge Labs, Inc.
9.40
−0.19 −2.03%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
89
PASS · shorts 89
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $431.2MP/E —DIV YIELD —FCF YIELD -20.43%REV TTM $10.4M +168.1%NET INCOME −$94.5MNET CASH $66.9M52W 4.80 – 25.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.5M | +1.6% | — | −$29.3M | −$26.1M | — | -0.58 | −$19.3M | $328K | −$19.6M | Aug 5 |
| Q1 2026 · Mar 31 | $2.8M | +91.0% | — | −$25.4M | −$22.3M | — | -0.52 | −$24M | $26K | −$24.1M | Aug 5 |
| Q4 2025 · Dec 31derived | $3.1M | — | — | −$28.4M | −$25.9M | — | -0.72 | −$28.3M | $112K | −$28.4M | Mar 24 |
| Q3 2025 · Sep 30 | $2.1M | — | — | −$23.1M | −$20.2M | — | -0.56 | −$16M | $22K | −$16.1M | Nov 6 |
| Q2 2025 · Jun 30 | $2.4M | — | — | −$24.8M | −$21.6M | — | -0.60 | −$20M | $159K | −$20.1M | Aug 5 |
| Q1 2025 · Mar 31 | $1.5M | — | — | −$16.4M | −$12.9M | — | -0.36 | −$17.4M | $426K | −$17.8M | Aug 5 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$25.4M | −$21.1M | — | 15.13 | −$5.1M | $26K | −$5.2M | Mar 24 |
| Q3 2024 · Sep 30 | $0 | — | — | −$24.8M | −$23.4M | — | -6.70 | −$14.9M | $305K | −$15.2M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$15.3M | −$13.6M | — | -7.94 | −$15.8M | $35K | −$15.8M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$12.8M | −$13M | — | -7.76 | −$15.7M | $0 | −$15.7M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.6M | −$21M | — | -12.53 | −$8.5M | $0 | −$8.5M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$9.9M | −$14.6M | — | -8.74 | — | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $9M | — | −$92.8M | −$80.6M | -896.1% | -2.24 | −$81.6M | $719K | −$82.3M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$78.2M | −$71.1M | — | -6.63 | −$51.5M | $366K | −$51.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$48.4M | −$63.9M | — | -38.17 | −$37.4M | $166K | −$37.5M | — | — |
Every number comes from BioAge Labs, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.